Clinical trial
Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for…
NCT00454818 · Celladon Corporation, Industry · Completed
Key facts
| NCT number | NCT00454818 |
|---|---|
| Title | Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure |
| Official title | A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts) |
| Acronym | CUPID |
| Lead sponsor | Celladon Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive, Dilated Cardiomyopathy |
| Intervention type | Genetic, Procedure |
| Interventions | MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study) |
| Enrollment | 51 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2012 |
| First posted | Apr 2, 2007 |
| Last update posted | Aug 20, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: